Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Factors to consider when treating AML and the importance of communicating with patients

Thomas Cluzeau • 12 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, shares his opinion on the goal of treatment in acute myeloid leukemia (AML), highlighting factors to consider when treating patients, and the importance of discussing and communicating with patients to better understand what is best. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Thomas Cluzeau

Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
Managing TP53-mutated MDS: current strategies and remaining therapeutic challenges
1:28
Managing TP53-mutated MDS: current strategies and remaining therapeutic challenges
Thomas Cluzeau • 13 Jun 2026
Recent advances in frontline treatment approaches for patients with LR-MDS
2:17
Recent advances in frontline treatment approaches for patients with LR-MDS
Thomas Cluzeau • 13 Jun 2026
Selecting patients with AML for transplant: key considerations & the role of enhanced MRD monitoring
2:38
Selecting patients with AML for transplant: key considerations & the role of enhanced MRD monitoring
Thomas Cluzeau • 13 Jun 2026

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals